my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain sub more
Syntaxin announced a manufacturing agreement with SynCo Bio Partners B.V. Under the agreement, SynCo will manufacture SXN101959, Syntaxin’s lead internal candidate for Acromegaly, discovered from its Targeted Secretion Inhibitor (TSI) platform. Acromegaly is a chronic and debilitating disease resul more
Syntaxin announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial more
Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, reports that Andrew Sandham has been appointed Executive Chairman. This follows the resignation of CEO, Patrick Doyle, for personal reasons. Mr Sandham has worked closely with Syntaxin since its form more
The function of the Munc18-1 protein hydrophobic pocket, which interacts with the syntaxin-1 N-terminal peptide, has been highly controversial in neurosecretion. Recent analysis of patients with familial hemophagocytic lymphohistiocytosis type 5 has identified the E132A mutation in the hydrophobic p more
In the killer lymphocyte, the targeted delivery of perforin‐ and granzyme‐containing cytotoxic granules to the immunological synapse is crucial for the eradication of pathogen‐infected or transformed targets. This process is achieved through a tightly controlled and highly efficient granule exocyt more
Abstract The Arabidopsis ATP‐binding cassette B19 (ABCB19, P‐glycoprotein19) transporter functions coordinately with ABCB1 and PIN1 to motivate long distance transport of the phytohormone auxin from the shoot to root apex. ABCB19 exhibits a predominantly apolar plasma membrane (PM) localization more
ValiRx Plc (ValiRx) is a publicly held biopharmaceutical company engaged in the development of novel technologies and products for the treatment of oncology related disorders. The product focus is in the epigenomic analysis and treatment of cancer and applied to other fields such as neurology and in more
About Biopharmaceutical Company - Developing Novel Biopharma Biotechnology Company About Syntaxin Biopharmaceutical Product Pipeline Biotech Research & Development Bio Tech News Contact Biopharmaceutical Firm Biopharma Company About Us History Board of Directors Management Team Investors Scientific more
Skip to Content combining biology and chemistry to create diversity About » Board of Directors Kate Bingham Kate is Managing Partner at SVLS with a focus on biotechnology having joined the company in SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK , US , Irelan more
Organelle Markers Knowledge of the subcellular location of a protein may reveal the potential role it plays in a variety of cellular processes. Colocalization with one of the organelle-specific antibodies listed here can confirm the subcellular location of a protein of interest. While these organell more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
